These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 25284275

  • 1. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
    Gordon KB, Gottlieb AB, Langely RG, van de Kerkhof P, Belasco KT, Sundaram M, Okun M, Serra L.
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):767-76. PubMed ID: 25284275
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 4. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
    Bissonnette R, Iversen L, Sofen H, Griffiths CE, Foley P, Romiti R, Bachinsky M, Rottinghaus ST, Tan H, Proulx J, Valdez H, Gupta P, Mallbris L, Wolk R.
    Br J Dermatol; 2015 Mar; 172(5):1395-406. PubMed ID: 25418186
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
    Papp K, Menter A, Poulin Y, Gu Y, Sasso EH.
    J Eur Acad Dermatol Venereol; 2013 May; 27(5):634-42. PubMed ID: 22429586
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
    Umezawa Y, Torisu-Itakura H, Morisaki Y, ElMaraghy H, Nakajo K, Akashi N, Saeki H, Japanese Ixekizumab Study Group.
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
    [Abstract] [Full Text] [Related]

  • 7. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Mar; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 8. Intermittent etanercept therapy in pediatric patients with psoriasis.
    Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G.
    J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
    Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH.
    J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R, Unnebrink K, Valdecantos WC.
    J Drugs Dermatol; 2015 Aug; 14(8):864-8. PubMed ID: 26267731
    [Abstract] [Full Text] [Related]

  • 11. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [Abstract] [Full Text] [Related]

  • 12. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
    Danesh MJ, Beroukhim K, Nguyen C, Levin E, Koo J.
    Dermatol Online J; 2015 Jun 16; 21(6):. PubMed ID: 26158370
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 Jun 16; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar 16; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 15. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.
    Br J Dermatol; 2008 Mar 16; 158(3):549-57. PubMed ID: 18047521
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM.
    J Am Acad Dermatol; 2010 Sep 16; 63(3):448-56. PubMed ID: 20605254
    [Abstract] [Full Text] [Related]

  • 17. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
    Gniadecki R, Leonardi CL, Gordon KB, Gu Y, Geng Z, Nader A, Teixeira HD.
    J Eur Acad Dermatol Venereol; 2018 Aug 16; 32(8):1297-1304. PubMed ID: 29524255
    [Abstract] [Full Text] [Related]

  • 18. Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study.
    Griffiths CE, Luger TA, Brault Y, Germain JM, Mallbris L.
    J Eur Acad Dermatol Venereol; 2015 Mar 16; 29(3):468-73. PubMed ID: 25087839
    [Abstract] [Full Text] [Related]

  • 19. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug 16; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.
    J Dermatolog Treat; 2012 Jun 16; 23(3):203-7. PubMed ID: 21787203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.